Clinical Trial Results:
Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akromegalie unter laufender Therapie mit Pegvisomant (Somavert);
Prospective, open-label study to evaluate the efficacy of the combined treatment of somatostatin analogue octreotide (Sandostatin) or dopamine agonist cabergoline (Dostinex) in patients with acromegaly on stable therapy of pegvisomant (Somavert).
|
Summary
|
|
EudraCT number |
2007-005585-12 |
Trial protocol |
DE |
Global completion date |
15 Jul 2009
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Mar 2020
|
First version publication date |
29 Mar 2020
|
Other versions |
|
Summary report(s) |
Results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.